These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25621779)

  • 1. [Treatment of metastatic castration-resistant prostate cancer].
    Caffo O
    Recenti Prog Med; 2015 Jan; 106(1):35-9. PubMed ID: 25621779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
    Davies RS; Smith C; Lester JF
    Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
    Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F
    World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
    Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
    Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; Mucciarini C; Zustovich F; Macrini S; Burgio SL; Santarossa S; D'Aniello C; Basso U; Tarasconi S; Cortesi E; Buttigliero C; Ruatta F; Veccia A; Conteduca V; Maines F; Galligioni E
    Eur Urol; 2015 Jul; 68(1):147-53. PubMed ID: 25457020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing of agents in castration-resistant prostate cancer.
    Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
    Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
    Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
    Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].
    Brodszky V; Péntek M; Baji P; Rencz F; Géczi L; Szûcs M; Berczi C; Gulácsi L
    Magy Onkol; 2014 Sep; 58(3):189-97. PubMed ID: 25260083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
    Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G
    Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?
    Hélissey C; Rouanne M; Arnaud FX; Le Moulec S
    Anticancer Drugs; 2015 Mar; 26(3):367-70. PubMed ID: 25486600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
    Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
    Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
    Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A
    Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
    Schmid SC; Geith A; Böker A; Tauber R; Seitz AK; Kuczyk M; von Klot C; Gschwend JE; Merseburger AS; Retz M
    Adv Ther; 2014 Feb; 31(2):234-41. PubMed ID: 24442834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
    Barqawi YK; Borrego ME; Roberts MH; Abraham I
    J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice.
    Lahcene H; Aprikian AG; Vanhuyse M; Hu J; Bladou F; Cury F; Kassouf W; Perreault S; Dragomir A
    J Oncol Pharm Pract; 2020 Mar; 26(2):293-305. PubMed ID: 30997868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.